From January 26 to 27, the 19th Asian Financial Forum was held in Hong Kong. This year's forum, themed "Multilateral Cooperation for a Shared Tomorrow", brought together over 3,600 political and business leaders, financial institutions, and industry representatives from more than 60 countries and regions. The Chairwoman of the Board of Sino Biopharm (1177.HK) was invited to attend the "Biopharma 2026: Trends, Challenges and Opportunities" roundtable forum to discuss pharmaceutical innovation, capital trends, and technological changes. 

In the opening remarks, John Ka Chiu Lee, Chief Executive of the Hong Kong Special Administrative Region, stated that with its robust and reliable financial regulatory system, a financial market with deep liquidity and product innovation, and world-class investor protection, Hong Kong continues to be the preferred destination for businesses seeking to grow in a safe and convenient business environment. 

He said that Hong Kong is focusing on three major areas to continue consolidating its status as an international financial center. First, strengthening its own advantages, including deepening the stock market, expanding the bond market, and promoting the development of the asset and wealth management industries. Second, accelerating the development of emerging areas, including establishing an international gold trading market and a commodity trading ecosystem in Hong Kong. Third, continuing to value international exchange and cooperation; for companies intending to redomicile to Hong Kong, we will provide assistance to facilitate their integration with the world and long-term development in this world-class city. 

At the roundtable forum, Ms. Theresa Tse pointed out that China is rapidly growing into a major engine for global biopharmaceutical innovation, and it is expected that by 2026, more than half of all new drug innovations could originate from China. 

When discussing the evolution of global and local investment trends, she believes that current investment is concentrating on areas such as immunology, metabolism, the central nervous system (CNS), and anti-aging. New therapies and technology platforms targeting these fields are becoming a global focus. In line with this trend, Sino Biopharm positions itself as the preferred partner connecting Chinese innovation with the global market. By integrating the constantly emerging innovation resources in China, the company engages in deep cooperation with domestic and international enterprises and research institutions to promote innovative achievements with international potential to the global market. In the past six months, the company has completed two landmark strategic acquisitions, LaNova Medicines and Hygieia, significantly expanding its footprint in differentiated technology platforms such as bispecific antibodies and Antibody-Drug Conjugates (ADCs), as well as in cutting-edge therapeutic areas like siRNA. This also reflects Sino Biopharm's core advantage: leveraging China's innovation momentum to jointly explore the global market with partners. 

As artificial intelligence accelerates its integration with the biopharmaceutical industry, Ms. Theresa Tse stated that AI is moving from the conceptual stage to a critical phase of delivering real value, showing potential in molecule generation and drug design, and has already produced numerous results. In the future, artificial intelligence will not only reduce R&D costs, improve efficiency, and accelerate clinical speed, but is also expected to break through previously "undruggable" targets. 

"When artificial intelligence develops to this stage and becomes the core innovative force for breaking through 'undruggable' targets, it will undoubtedly yield huge returns. This will be a major opportunity in the healthcare market, which is truly exciting." said Ms. Theresa Tse. 

Disclaimer:
The copyright of this article is owned by the original author or the Company. It may not be used by reprinting, copying, filming, adapting, compiling, or other means without authorization. The portrait rights for any individuals appearing in this article belong to the individuals themselves. Unauthorized use is prohibited. 

Source: Office of the Government of the HKSAR in Beijing, China Fund News